<DOC>
	<DOCNO>NCT01904539</DOCNO>
	<brief_summary>This phase 1 study evaluate safety single 10 mg dose obeticholic acid ( OCA ) healthy volunteer patient liver disease .</brief_summary>
	<brief_title>Hepatic Impairment Trial Obeticholic Acid</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>Subject Inclusion Criteria All Subjects Female male subject ≥ 18 year age Subjects minimum body weight 45 kg body mass index ( BMI ) &gt; 18 kg/m2 . Contraception : Female subject must postmenopausal , surgically sterile , premenopausal , prepare use ≥ 1 effective method contraception trial least 30 day administration OCA . Subjects must provide write informed consent agree comply trial protocol . Subjects Hepatic Impairment : Evidence hepatic disease 1 . Score ≥ 2 one ChildPugh parameter , 2 . Histological diagnosis cirrhosis presence esophageal varix , 3 . Abnormal alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) level Subjects satisfy criterion modify ChildPugh classification hepatic impairment Screening : 1 . Mild hepatic impairment : Class A ( ChildPugh Scores 56 point ) 2 . Moderate hepatic impairment : Class B ( ChildPugh Scores 79 point ) 3 . Severe hepatic impairment : Class C ( Child Pugh Scores 1015 point ) Healthy volunteer : Absence clinicallyrelevant abnormality identify detailed medical history , full physical examination , 12lead ECG Clinical laboratory test within normal reference range Subjects must within ± 10 year mean age within 20 % mean BMI hepatic impaired subject ( ChildPugh category A , B , C ) Subject Exclusion Criteria All Subjects Positive test human immunodeficiency virus ( HIV ) 1 HIV2 screen Presence history malignancy , exception basal cell carcinoma Received investigational drug , include OCA , within 30 day t½=5 prior dose Blood plasma donation within 30 day prior dose History noncompliance medical regimen , subject consider potentially unreliable Presence history clinically significant cardiac arrhythmia may prohibit subject participate trial Female subject pregnant lactate Subjects irritable bowel disease GI disorder potential alter drug bile acid absorption . Subjects history gall bladder removal , gastric bypass GI surgery may affect drug absorption enterohepatic circulation . Subjects Hepatic Impairment History alcohol drug abuse 3 month prior dose In opinion Investigator medical monitor , fluctuate rapidly deteriorate hepatic function within screen period In opinion Investigator , evidence additional severe uncontrolled systemic disease evidence significant clinical disorder laboratory find likely affect conduct trial interpretation data Subjects transjugular intrahepatic portosystemic shunt and/or undergone portacaval shunt Subjects Wilson 's disease , alpha1 antitrypsin deficiency , glycogen storage disease galactosemia Heavy smoker use tobacco nicotine product Healthy Volunteers Presence significant uncontrolled disease complicate execution trial interfere absorption , distribution , metabolism , excretion drug via gut Evidence chronic acute liver disease document medical history , physical examination diagnostic test likely affect conduct trial interpretation data History and/or current alcohol abuse ( define consumption 210 mL alcohol per week ; equivalent fourteen 4oz glass wine , fourteen 12oz cans/bottles beer wine cooler per week ) drug abuse within prior two year Smoke use tobacco nicotine product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>